An interventional study of adaptive stereotactic body radiation therapy (SBRT) with a SIB in Prostate Cancer (Adenocarcinoma), sponsored by Fox Chase Cancer Center. Suspended at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Fox Chase Cancer Center · Not applicable, Interventional, and Treatment
Pending interim analysis
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Fox Chase Cancer Center.
Among the 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 14th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center is open now. The open studies under Prostatic Neoplasms, anywhere →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 1
First in 1998; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 116 across the 13 interventional studies, 854 across the 1 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fox Chase Cancer Center is the lead sponsor of 216 studies on the registry; 29 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
The main questions this trial aims to answer are:
Participants will:
Visit the clinic for check-ups and tests:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: adaptive stereotactic body radiation therapy (SBRT) with a SIB
This is a phase 1 dose finding study investigating escalated doses of adaptive prostate SBRT for patients with intermediate and favorable high risk prostate cancer. There will be a Bayseian Optimal Interval Design (BOIN) defining the dose escalation parameters and the dose will escalate as per Section 5.0. Treatment is 5 fractions every other day and will be expected to be typically completed in 2-3 calendar weeks.
Severe (CTCAE grade ≥ 3) treatment-related (possibly, probably or definitely) toxicity occurring within 90 days of treatment.
Time frame: From initiation of treatment to 90 days after end of treatment, for a duration of ~100 days.
Biochemically progression free survival
Time from the end of treatment administration to biochemical progression (using Pheonix definition), local, regional, or distant progression, initiation of additional prostate cancer therapy, or death. Patients who are alive and have not experienced any progression or initiated any additional prostate cancer therapy by the end of follow up are considered censored.
Time frame: From end of treatment to biochemical, local, regional or distant progression, or initiation of additional prostate cancer therapy or death, or end of follow up for a total of up to 5 years.
Local failure free survival
Time from the end of treatment administration to local progression or death. Patients who are still alive and have not had local progression by the end of follow up are considered censored.
Time frame: From end of treatment to local progression or death or end of follow up for a total of up to 5 years.
PSA response
The PSA response will be assessed by the post-treatment PSA nadir and time to nadir.
Time frame: From end of treatment to end of follow-up for a total of up to 5 years.
The proportion of patients who have a decrease greater than or equal to the acute minimum clinically important difference (MID) in EPIC-26 scores among the urinary, bowel and sexual function domains at 3 and 6 months post-treatment compared to baseline
Time frame: From enrollment to 6 months post-treatment.
The proportion of patients who have a decrease greater than or equal to the minimum clinically important difference (MID) in EPIC-26 scores among the urinary, bowel and sexual function domains at 1 and 2 years post-treatment compared to baseline.
Time frame: From enrollment to 2 years post-treatment for a duration of ~ 2.5 years.
Distant metastasis free survival
Time from the end of treatment administration to distant metastasis or death. Patients who are still alive and metastasis-free at the end of follow up are considered censored.
Time frame: From end of treatment to distant metastasis or death or end of follow up, for a total of up to 5 years.
The proportion of patients who had at least one optimal treatment planning criteria not met, the number of criteria not met per patient, and the number of criteria not met per organ site.
These proportions will be assessed in the overall population and per dose level.
Time frame: From radiation simulation to end of treatment for a duration of 2-3 months.
Started Sep 2025 (actual). Primary completion is estimated for Aug 2033, 94 months after the start.
How these figures are worked out, and which studies are left out of them.
Pending interim analysis
Pending interim analysis
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.